<DOC>
	<DOCNO>NCT03001830</DOCNO>
	<brief_summary>The GO-8 study focus assess safety efficacy gene therapy patient severe haemophilia A</brief_summary>
	<brief_title>Gene Therapy Haemophilia A .</brief_title>
	<detailed_description>Haemophilia A x-linked , life threaten bleed disorder arise defect coagulation factor VIII ( FVIII ) gene . Current treatment haemophilia A , commonest inherit bleed disorder ( prevalence 1 5000 individual ) consist life-long , 2-3X/week , intravenous injection clot factor concentrate , demand , exceedingly expensive widely available curative . In contrast , gene therapy offer potential cure haemophilia A illustrate first unequivocal success relate condition , haemophilia B . In study investigator show single intravenous administration serotype 8 base adeno-associated virus , ( AAV8 ) vector encode factor IX ( FIX ) gene result stable ( &gt; 6 year ) therapeutic expression FIX without long-lasting toxicity . The investigator plan use AAV8 platform evaluate novel FVIII expression cassette , AAV2/8-HLP-FVIII-V3 , patient haemophilia A . Extensive preclinical study demonstrate AAV2/8-HLP-FVIII-V3 lead long-term , endogenous expression FVIII mouse non-human primate model without toxicity even fifty-fold high dos propose start clinical trial dose use . Therefore , open label , Phase I/II dose escalation study entail single systemic administration AAV2/8-HLP-FVIII-V3 adult ( &gt; 18 year age ) severe haemophilia A baseline factor FVIII level &lt; 1 % normal design establish safety efficacy approach . Dosing begin 6x10^11 vector genome ( vg ) /kg progress sequentially 2x10^12vg/kg ultimately 6x10^12vg/kg absence toxicity . A minimum 2 patient recruit dose possibility expand dose cohort maximum 6 patient base safety efficacy . The study duration patient 15 year vector infusion .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Adult male , age 18 year , confirm diagnosis severe Haemophilia A define baseline plasma FVIII level &lt; 1 % normal assess validated onestage clot assay chromogenic assay , result intron 22 inversion , intron 1 inversion , splicesite mutation , small deletions/insertions missense mutation . A severe bleeding phenotype define least one following : 1 . On prophylaxis history bleeding , 2 . On demand therapy current past history 4 bleeding episodes/year , 3 . Evidence chronic haemophilic arthropathy ( pain , joint destruction , loss range motion ) Received treatment human FVIII concentrate least &gt; 50 exposure day ; Able give full inform consent able comply requirement trial include 15year longterm followup ; Willing practice barrier contraception vector administration least three consecutive semen sample negative vector sequence ( may 23 month ) . Presence neutralise antihFVIII antibody ( inhibitor , determine Bethesda inhibitor assay ) time enrolment previous history hFVIII inhibitor ; Severe haemophilia A patient large deletion ( multiple exon ) nonsense mutation F8 gene . Use investigational therapy haemophilia within 30 day enrolment ; Subjects active hepatitis B C , HBsAg HCV RNA viral load positivity , respectively currently antiviral therapy hepatitis B C. ( Negative viral assay two sample , collect least six month apart , require consider negative . Both natural clearers clear HCV antiviral therapy eligible ) . Serological evidence HIV1 CD4 count ≤ 200/mm3 . Subjects HIVpositive stable , adequate CD4 count ( &gt; 200/mm3 ) undetectable viral load measure twice six month prior enrolment , antiretroviral drug regimen eligible enrol . Evidence liver dysfunction ( persistently elevate ALT &gt; 1.5X upper limit normal ) ; Uncontrolled glaucoma , diabetes mellitus , hypertension ( systolic BP consistently ≥140 mmHg diastolic BP consistently ≥90 mmHg ) ; History malignancy ; Suspicious Lung lesion CT scan raise possibility cancer premalignant pathology Presence liver abnormality suspicious malignancy screen liver ultrasound Patients uncontrolled cardiac failure unstable angina ; Detectable neutralise antiAAV8 antibody Received AAV vector , gene transfer agent previous 6 month History active tuberculosis , fungal disease chronic infection Subjects unwilling provide require semen sample XVI . Poor performance status ( WHO score &gt; 1 ) XVII . Previous history family history venous arterial thromboembolism</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>